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ABSTRACT: The peptide angiotensin-converting enzyme inhibitors captopril and
lisinopril are unexpectedly shown to exhibit critical aggregation concentration
(CAC) behavior through measurements of surface tension, electrical conductivity,
and dye probe fluorescence. These three measurements provide similar values for the
CAC, and there is also evidence from circular dichroism spectroscopy for a possible
conformational change in the peptides at the same concentration. Cryogenic
transmission electron microscopy indicates the formation of micelle-like aggregates
above the CAC, which can thus be considered a critical micelle concentration, and
the formation of aggregates with a hydrodynamic radius of ∼6−7 nm is also
evidenced by dynamic light scattering. We also used synchrotron radiation X-ray
diffraction to determine the single-crystal structure of captopril and lisinopril. Our
results improve the accuracy of previous data reported in the literature, obtained
using conventional X-ray sources. We also studied the structure of aqueous solutions
containing captopril or lisinopril at high concentrations. The aggregation may be
driven by intermolecular interactions between the proline moiety of captopril molecules or between the phenylalanine moiety of
lisinopril molecules.
■ INTRODUCTION
Angiotensin-converting inhibitors are a class of drugs mainly
used for the treatment of high blood pressure and heart failure.
High blood pressure can result from the overproduction of
angiotensin by the angiotensin-converting enzyme (ACE).1,2
Captopril3−5 and lisinopril6−8 are drugs designed to inhibit
ACE activity by binding to the active site of ACE,
consequently inhibiting the conversion of angiotensin. Both
captopril and lisinopril are peptide analogues since the
captopril structure is inspired by the sequence of the Brazilian
snake Bothrops jararaca venom peptide,9 while lisinopril is a
synthetic modification of captopril. However, they differ in
their functional binding group: captopril has a thiol-functional
binding group, while lisinopril has a dicarboxyl-functional
binding group (Scheme 1).10,11
Captopril and lisinopril are the active agents in many
pharmaceutical formulations prescribed as ACE inhibitor
drugs.12 Captopril is prescribed for the treatment of congestive
heart failure and other high blood pressure-related dis-
eases.13,14 Lisinopril shares similar active properties to
captopril, which is used to treat several cardiac-related
infections or malfunctions.15−18
Very recently, captopril and lisinopril were evaluated as
antiviral drugs in the worldwide fight against the COVID-19
pandemic caused by the SARS-CoV-2 virus. Spike proteins on
the surface of SARS-CoV-2 bind to ACE2 receptors, which the
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Scheme 1. Chemical Structures for (a) Captopril and (b)
Lisinopril
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virus uses to get into human cells. Since the proposed
mechanism of activity of captopril and lisinopril involves
interference in the production of angiotensin 2 or blocking
ACE2, clinical trials to test captopril or lisinopril use in treating
COVID-19 are underway.19 Another recently described
application demonstrates the ability of captopril to inhibit
amyloid fibril formation.20 Many other peptides are being
researched as ACE2 inhibitors due to the high level of current
interest in potential COVID-19 treatments.21−23
Due to their potential activity as antiviral drugs and since
captopril and lisinopril are active in a fluid environment, it is
valuable to study their behavior in solution. Here, we study for
the first time the aggregation of captopril and lisinopril in
aqueous solution. This is motivated by the observation that the
molecules may show self-assembly behavior, although this has
not been explored, to the best of our knowledge. In addition,
we performed synchrotron radiation X-ray diffraction (SR-
XRD) to confirm previously reported single-crystal struc-
tures.24−28 A powerful combination of fluorescence, circular
dichroism (CD), and cryogenic-transmission electron micros-
copy (Cryo-TEM) methods was used to probe the self-
assembly of captopril and lisinopril in solution. Cryo-TEM
reveals the presence of micellar structures that form above
critical aggregation concentrations (CACs) determined from
fluorescence probe and CD spectroscopy measurements.
■ EXPERIMENTAL SECTION
Materials. Captopril and lisinopril (Mwcaptopril = 217.29 g/mol and
Mwlisinopril = 441.52 g/mol; the chemical structure is displayed in
Scheme 1) were purchased from Sigma-Aldrich (UK) and used as
received. Samples for solution characterization were prepared by
dissolving weighed amounts of captopril or lisinopril with weighed
amounts of ultrapure water (18 MΩ ThermoFisher Barnstead).
Samples for crystallization were prepared by mixing weighed amounts
of captopril or lisinopril with measured volumes of diethyl ether. The
pH measurements were performed with a Mettler Toledo FiveEasy
pH meter with a Sigma-Aldrich micro-pH combination electrode
(glass body).
Mass Spectroscopy. All reagents were of LCMS grade. Samples
were diluted to a final concentration of 30 μg/mL in water. 5 μL of
the sample was injected into a Thermo Scientific Accela HPLC. The
LC buffers were (A) water and (B) acetonitrile, both with 0.1%
formic acid. The column used for high-performance liquid
chromatography (HPLC) was a Thermo Hypersil Gold 2.1 × 50
mm C18 column, with a particle size of 1.9 μm and a pore size of 175
Å.
The mass spectrometer used was a Thermo Scientific LTQ-
Orbitrap-XL. MS1 scans were performed on the Orbitrap at 100 K
resolution in positive ion mode scanning across the 85−2000 m/z
range. A lock mass was used (413.266230 g mol−1). Our mass spectra
(shown in Supporting Information, Figure S1) confirm the high purity
of the purchased samples, with peaks corresponding to the expected
products and no evidence for contaminants.
Fluorescence Spectroscopy. The fluorescence probe 8-anilo-1-
naphthalenesulfonic acid (ANS) was used to locate the CAC. The
ANS fluorophore is sensitive to the hydrophobicity of its surrounding
environment,29 making it suitable to determine a CAC value resulting
from hydrophobic collapse. Samples for ANS were prepared by the
dilution of a mother sample prepared as 1.6 wt % captopril or 1.4 wt
% lisinopril in 2 × 10−3 wt % ANS. Spectra were recorded with a
Varian Cary Eclipse fluorescence spectrometer with samples in 4 mm
inner width quartz cuvettes. ANS assays were performed by measuring
spectra from 400 to 670 nm (λex = 356 nm). Results from the ANS
assays were analyzed as I/I0 versus concentration c, where I is the
maximum intensity of emission for solutions with captopril or
lisinopril, while I0 is the maximum emission intensity for the ANS
solution with no additives.
Surface Tension. The critical micellar concentration (CMC) was
determined by measuring the static surface tension Γ as a function of
the concentration of the solution using the Du Noüy ring method. An
automatic processor tensiometer (Krüss, model K12) which provides
a temperature-controlled (±0.1 °C) environment for the sample was
used to measure Γ at 20 °C. A series of solutions of captopril or
lisinopril in doubly distilled deionized water were obtained by the
sequential dilution of a concentrated stock solution. An equilibration
period of 15 min was allowed before the measurement of Γ for each
concentration.
Electrical Conductivity. The conductivity κ was measured for the
solutions of captopril and lisinopril using a Hanna Primo5
conductivity meter calibrated with a 1413 μS cm−1 calibration
solution. The measurements were recorded three times for each
concentration (the mean value is presented), starting from the most
dilute to the most concentrated solution.
CD Spectroscopy. CD spectra were recorded using a Chirascan
spectropolarimeter (Applied Photophysics, UK). Solutions were
placed between parallel plates (0.01 mm path length). Spectra were
measured with a 0.5 nm step, 1 nm bandwidth, and 1 s collection time
per step. The CD signal from the water background was subtracted
from the CD data of the sample solutions. The sample dilution series
was started from a 1.6 wt % captopril or from a 1.7 wt % lisinopril
mother solution. The range of concentrations studied by CD includes
the range of concentrations studied for the ANS assay using
fluorescence spectroscopy.
Fourier-Transform Infrared Spectroscopy. Spectra were
recorded using a Thermo Scientific Nicolet iS5 instrument equipped
with a DTGS detector, with a Specac Pearl liquid cell (sample
contained between fixed CaF2 plates). Spectra (1 wt % sample in
H2O) were scanned 128 times over the range of 900−4000 cm−1.
Dynamic Light Scattering. Experiments were performed using
an ALV CGS-3 system with a 5003 multidigital correlator. The light
source was a 20 mW He-Ne laser, linearly polarized, with λ = 633 nm.
A fixed scattering angle θ = 90° was used for all the experiments.
Solutions were filtered through 0.20 μm Anotop filters from Whatman
into standard 0.5 cm diameter cylindrical glass cells. Dynamic light
scattering (DLS) experiments measured the intensity correlation
function g(θ, t), where t is the lag time. A cumulant analysis algorithm
built in the ALV CGS-3 system acquisition software was used to
calculate the size-weighted distribution function from g(θ, t).
Cryogenic Transmission Electron Microscopy. Experiments
were performed using a field-emission cryo-electron microscope
(JEOL JEM3200FSC), operating at 200 kV and at −187 °C,
configured in the bright field mode and zero-loss energy filtering
(omega type) with a slit width of 20 eV. The sizes of selected
nanoassemblies were measured from photographs recorded using a
Gatan Ultrascan 4000 CCD camera. Vitrified specimens were
prepared on QUANTIFOIL 3.5/1 holey carbon copper grids (hole
size of 3.5 μm). The grids were first plasma cleaned using a Gatan
Solarus 9500 plasma cleaner and then transferred into the
environmental chamber of an automated FEI Vitrobot device at
room temperature and 100% humidity. Thereafter, 3 μL of the sample
solution was applied on the grid, which was blotted twice for 5 s and
then vitrified in a 1:1 mixture of liquid ethane and propane at a
temperature of −180 °C. The grids with the vitrified sample solution
were maintained at liquid nitrogen temperature and then cryo-
transferred to the microscope.
Crystal Preparation. Crystals were obtained by evaporating
aliquots of 7 wt % captopril or 0.2 wt % lisinopril dissolved in diethyl
ether on a microscopic slide placed inside a Petri dish. A second Petri
dish was placed on top, and a small aperture was allowed between the
Petri dishes to allow for the slow evaporation of diethyl ether over a
period of 1 week. Thereafter, the aperture between the Petri dishes
was closed. The crystals were stored on microscopic slides contained
inside the Petri dishes sealed with parafilm until SR-XRD experiments.
Synchrotron Radiation X-ray Diffraction. Measurements were
performed on experiment hutch 1 (EH1) of Beamline I19 at the
Diamond Light Source.30 The data were collected at a wavelength of
0.6889 Å on a Fluid Film Devices 3-circle fixed-chi diffractometer
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using a Dectris Pilatus 2 M detector. The crystal was mounted on a
MiTeGen micromount using perfluoropolyether oil and cooled for
data collection by a cryostream nitrogen-gas stream.31 The collected
frames were integrated using DIALS,32 as implemented by xia2,33 and
the data were corrected for absorption effects using a DIALS scale,34
an empirical method. The structure was solved by dual-space
methods35 and refined by least-squares refinement on all unique
measured F2 values.36
■ RESULTS AND DISCUSSION
We first determined the crystal structure of the two molecules,
which also provides a quality control of the compounds studied
in this work. Previous works report the crystal structure of
captopril24−26 or lisinopril27,28 determined using conventional
X-ray sources. Here, by using SR-XRD, we examine the
accuracy and improve the resolution of the crystal structure
already reported.
A number of methods have been used before to obtain
captopril or lisinopril crystals. In a previous work, captopril
crystals have been grown by the vapor-diffusion technique
using ethyl acetate as the solvent and petroleum ether as the
precipitant.24 Captopril crystals were also obtained by slow
evaporation from acetone or tetrahydrofuran−water solu-
tions.26 Lisinopril crystals were obtained by the vapor-diffusion
technique using water as a solvent and acetonitrile as the
precipitant.27 Other groups explored the controlled dehydra-
tion of lisinopril crystals by recrystallizing the material from
water solutions.28 Here, both captopril and lisinopril crystals
were obtained by the evaporation of solutions of these
materials in diethyl ether. Lisinopril crystals had a tendency
to dry in compact crystalline aggregate structures. Therefore,
the solutions of lisinopril used for crystallization were relatively
diluted to avoid the formation of uniform plaques of crystals
on the dried surfaces. Figure 1a,b shows the photographs of the
crystals obtained by the evaporation of solutions containing 7
wt % captopril in diethyl ether (Figure 1a) or 0.2 wt %
lisinopril in diethyl ether (Figure 1b). Square crystals of
captopril similar to those displayed in Figure 1a, already
reported in the literature, are the alternative to plate-like
crystals of captopril associated with the disulfide bridged
captopril dimer.26 Lisinopril has been reported to crystallize in
flexible-like needles,27 in contrast to the rectangular crystals in
Figure 1b.
The crystals shown in Figure 1a,b were sufficiently large to
enable synchrotron single-crystal XRD structure determina-
tion. Crystal structure determination showed that captopril
crystallizes in an orthorhombic P212121 structure, with unit cell
parameters (Table 1 and Figure 2a) very similar to those
reported in the literature for crystals grown by the vapor-
diffusion technique using ethyl acetate as the solvent and
petroleum ether as the precipitant.24 There was no evidence
for captopril dimerization (due to disulfide bond forma-
tion)37−40 in the obtained crystal structure or diffraction data.
The lisinopril crystal structure is sensitive to the humidity of
the sample. Powder XRD was used to prove that lisinopril can
be crystallized in its monohydrate, dihydrate, or anhydrous
forms depending on crystal hydration.28 Here, lisinopril
crystallizes in a monoclinic P21 structure, with unit cell
parameters (Table 1 and Figure 2b) very similar to those
reported in the literature for single-crystal lisinopril dehy-
drate.28 Figure 3 shows the atom numbering corresponding to
the unit cell structures shown in Figure 2.
Having determined the crystal structure of the compounds,
we examined potential aggregation and self-assembly in
aqueous solution. A powerful combination of methods
sensitive to colligative properties and the formation of
hydrophobic domains was used, that is, surface tensiometry,
electrical conductivity, and dye probe fluorescence measure-
ments.41−48
Fluorescence measurements performed using ANS were
undertaken to identify any CAC of captopril or lisinopril in
water. Figure 4a,b shows the dependence of the normalized
maximum intensity I/I0 as a function of the concentration.
Figure 4a,b shows that the intensity of the ANS fluorescence
emission grows, while the emission wavelength decreases with
the increasing additive concentration. This result is character-
istic of hydrophobic pocket formation with the increasing
concentration of captopril or lisinopril. CAC values can be
determined from the discontinuity in the dependence of I/I0
with the concentration, as indicated for captopril (Figure 4a)
and lisinopril (Figure 4b).
The concentration dependence of surface tension is shown
for captopril and lisinopril in Figure 4c,d, respectively.
Discontinuities in the concentration dependence and leveling
out of the surface tension at higher concentration are
characteristic of CMC behaviour,44,49,50 and the values
indicated in the figure are in very good agreement with
those obtained from the fluorescence probe measurements
(Figure 4a,b).
Electrical conductivity is another colligative property
measurement sensitive to molecular aggregation which
influences the number of ions present in solution. In the
case of captopril and lisinopril, ionization is associated with the
C-terminal carboxylate for both molecules and the lysine ε-
amine group for lisinopril. The pH of solutions of the two
peptides was measured as a function of concentration
(Supporting Information, Figure S2). The pH at concen-
trations above the CAC for captopril is below pH 3. This is
close to the expected pKa of the carboxyl terminus
18 ensuring a
significant proportion of charged carboxyl groups. For
lisinopril, the pH plateaus at pH 5.4, which is substantially
Figure 1. Representative images for crystals obtained by evaporating
drops of (a) 7 wt % captopril in diethyl ether or (b) 0.2 wt % lisinopril
in diethyl ether on a microscope slide.
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below the expected pKa = 10.5 for the lysine residue,
18 so this
residue will be charged as well as the carboxyl terminus. A
discontinuity in electrical conductivity against concentration is
also often used to detect micellization.44,50 Remarkably, both
captopril and lisinopril show discontinuities in conductivity as
a function of concentration, as shown in Figure 4e,f,
respectively. The indicated CAC/CMC values are in excellent
agreement with those obtained from the other two
independent methods.
Our data from three independent measurement techniques
thus indicate that both captopril and lisinopril aggregate in
aqueous solution above ca. 0.1−0.2 wt %, specifically (5.5 ±
1.4) mM for captopril and (3.4 ± 1.0) mM for lisinopril. We
emphasize the fact that both compounds crystallize into well-
defined structures consistent with prior data, which is
consistent with high-purity samples. This was also confirmed
by our own mass spectrometry analysis (Supporting
Information, Figure S1), so changes in colligative property
data with concentration are not consistent with the presence of
impurities. Fourier-transform infrared spectroscopy (FTIR)
spectra were measured to check for the presence of possible
dimers of captopril which can form in aqueous solution.37−40
The spectrum shown in Supporting Information, Figure S3
shows the presence of a peak at 2566 cm−1, which is assigned
to the S−H stretching mode of free captopril molecules.40 This
indicates that in the solutions studied, captopril is present
mainly in the undimerized form.
Figure 5a,b shows the dependence of the CD signal
measured for the same range of captopril or lisinopril
concentrations as in Figure 4. The CD spectra provide
conformational information on the peptide structures due to
the amide backbone and the side groups.51,52
The CD spectra for captopril are characterized by a
pronounced minimum at 203 nm (Figure 5a). The CD data
reported in the literature for 1.3 × 10−3 wt % captopril53 and
for 1.8 × 10−3 wt % captopril54 in water display a negative peak
at 210 or 208 nm, close to 203 nm reported in Figure 5a,
which was ascribed to the contributions from the n → π*
transition of the carboxylate group and from the n → σ*
Table 1. Crystallographic Data for Captopril and Lisinopril
captopril lisinopril
bond precision/Å C−C = 0.0067 C−C = 0.0086
wavelength/Å 0.68890 0.68890
chemical formula C9H15NO3S C21H31N3O5·2H2O
formula weight 217.28 441.52
crystal system orthorhombic monoclinic


















unique reflections/Rint 1838/0.0784 3733/0.1084
abscorr type, Tmin, Tmax empirical, 0.997, 1.000 empirical, 0.999, 1.000
diffrn_measured_fraction_theta_full 99.5 99.0
theta (max) 24.212 24.274
R1 [F
2 > 2σ], wR2 [all data] 0.0486, 0.1050 0.0492, 0.1087
goodness of fit (S) 0.935 0.796
parameters 137 316
Figure 2. Unit cells for (a) captopril and (b) lisinopril calculated
using the parameters in Table 1.
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transition of the amino group of the proline moiety (Scheme
1a).54−56 Peaks in this range are also affected by backbone
amide π−π* and n−π* transitions.56,57 The CD spectra
indicate that captopril does not form any organized secondary
structure under the conditions studied. This is in contrast to
some of the amino acids discussed in ref 55, which form fibrils
at sufficiently high concentration, for example, phenylalanine58
or tryptophan.59 Figure 5a also reveals a slight red shift in the
position of the minimum upon reducing the concentration
from 203 nm at high concentration to 205−208 nm for the
lowest concentrations. This is consistent with the observation
in ref 53, which reports a red shift on increasing pH (in our
measurements, reducing concentration corresponds to higher
pH; Supporting Information, Figure S2). In the case of ref 53,
however, pH was varied at a fixed concentration.
The CD spectra for lisinopril are characterized by two
minima at 186 and 222 nm and one maximum at 197 nm
(Figure 5b). To the best of our knowledge, CD data have not
previously been reported for lisinopril solutions. The positive
peak in the CD spectra at 197 nm may be influenced by π−π
stacking interactions due to the stacking of the aromatic ring in
the phenylalanine moiety (which typically gives a peak at 210−
230 nm) (Scheme 1b).55,60,61 Phe−Phe excitonic coupling
contributions can significantly influence the peak position,62,63
as can such contributions from proline.55 The minima at 186
and 222 nm are influenced by the aforementioned amide
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backbone electronic transitions as well as the n→ π* transition
of the carboxylate group and the n → σ* transition of the
amino group of the proline moiety (Scheme 1b).51,54,55 In
contrast to the case of captopril, there is no evidence for a
concentration-dependent red shift in the CD spectra for
lisinopril in Figure 5b.
The data in Figure 5a,b were used to generate the plots
displayed in Figure 5c,d. Figure 5c shows the dependence of
the ellipticity at 203 nm, [θ]203, with concentration of
captopril, while Figure 5d shows the dependence of [θ]197
with the concentration of lisinopril.
The data in Figure 5c,d follow similar patterns. Both [θ]203
and [θ]197 increase sharply with concentration until they reach
a constant value at ccaptopril = clisinopril − 0.2 wt %. This is
assigned as the CAC for these molecules. Intermolecular
interactions between proline moieties of captopril or between
aromatic units in the phenylalanine moiety of lisinopril are
saturated at concentrations higher than 0.2 wt % and therefore
become independent of concentration. This process is
correlated with the cooperative formation of hydrophobic
pockets with increasing concentration, as revealed by the ANS
fluorescence results shown in Figure 4a,b.
Cryo-TEM is a powerful method to image nanostructures in
self-assembled materials based on the vitrification of aqueous
solutions, avoiding artefacts due to sample drying in the
preparation of samples for conventional TEM or atomic force
microscopy. Cryo-TEM was used to image the self-assembled
nanostructures at a concentration well above the CAC of
captopril and lisinopril. Representative cryo-TEM images are
shown in Figure 6a,b for 1 wt % solutions of captopril and
lisinopril, respectively. Both cryo-TEM images reveal the
formation of very small aggregates in solution, <10 nm in
diameter. These appear to be spherical micelle-like structures.
These are not present in control images obtained for 0.05 wt %
aqueous solutions (below the CAC) shown in Supporting
Information, Figure S4.
DLS confirms the presence of the self-assembled aggregates
revealed by cryo-TEM images. Figure 7a shows the intensity
correlation functions measured for 1 wt % captopril or
lisinopril. The size-weighted distribution functions calculated
from the data in Figure 7a show the presence of aggregates
with a hydrodynamic radius of RH = 6 or 7 nm in 1 wt %
solutions of captopril or lisinopril, respectively (Figure 7b).
■ CONCLUSIONS
The combination of surface tensiometry, electrical conductiv-
ity, and dye fluorescence measurements provides evidence for
Figure 4. CAC measured by (a,b) ANS fluorescence, (c,d) surface tension, and (e,f) conductivity for captopril and lisinopril solutions.
Figure 5. CD spectra as a function of the concentration for solutions
containing (a) captopril and (b) lisinopril. (c) Concentration
dependence of [θ]203 determined from the spectra in (a). (d)
Concentration dependence of [θ]197 [from (b)].
Figure 6. Cryo-TEM images for 1 wt % aqueous solutions of (a)
captopril and (b) lisinopril.
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the critical aggregation behavior of captopril and lisinopril in
water. The consistency between break points in the
concentration dependence of these three independent
measurements provides high confidence in the existence of a
critical aggregation phenomenon in both peptides. Surface
tensiometry and electrical conductivity probe distinct types of
colligative properties of the molecules, that is, surface assembly
and ionic properties in solution, respectively. On the other
hand, dye probe fluorescence measurements are sensitive to
the formation of local hydrophobic environments. The CAC
detected also corresponds to the concentration at which
discontinuities are observed in the CD spectra (molar
ellipticity at a fixed wavelength corresponding to maxima/
minima in the spectra). This suggests that the aggregation may
be driven by a molecular conformational switch, which is pH-
dependent as suggested by concentration-dependent pH
measurements.
The obtained cryo-TEM images and DLS data consistently
reveal the presence of small micelle-like aggregates in solution
with a diameter <10 nm. The self-assembly of captopril and
lisinopril into micelles above a CAC/CMC is not expected
based on their molecular structures which do not show typical
surfactant characteristics, that is, a lengthy hydrophobic tail
group and a hydrophilic head group. However, both molecules
bear hydrophobic regions and hydrophilic regions since both
molecules have carboxyl units at the C terminus, and lisinopril
also bears a cationic lysine residue with the amine unit. We
suggest that the hydrophobic interactions between the proline
moieties in captopril molecules or the phenylalanine (and/or
proline) units in lisinopril molecules respectively balanced by
electrostatic interactions may lead to the self-assembly into
micelles and that the self-assembly process is driven by a
conformational change at the CAC.
We also provide for the first time the SR-XRD crystal
structure of captopril and lisinopril. The crystal structures for
both agree with previously published laboratory XRD data.
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